Urovant Sciences, a clinical-stage biopharmaceutical company, is focused on developing and commercializing innovative therapies for urologic conditions. Their lead product candidate, vibegron, is an oral, once-daily small molecule beta-3 agonist being evaluated for overactive bladder (OAB). The company reported positive data from a phase 3 pivotal study and submitted a New Drug Application to the FDA seeking approval for vibegron. Urovant's second product candidate, URO-902, is a novel gene therapy for OAB patients who have failed oral pharmacologic therapy. The company, owned by Sumitomo Dainippon Pharma Co., Ltd., aims to develop treatments for additional urologic diseases.